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Abstract
The gene encoding the human formyl peptide receptor 1 (FPR1) is heterogeneous, containing numerous single nucleotide
polymorphisms (SNPs). Here, we examine the effect of these SNPs on gene transcription and protein translation. We also
identify gene promoter sequences and putative FPR1 transcription factors. To test the effect of codon bias and codon pair
bias on FPR1 expression, four FPR1 genetic variants were expressed in human myeloid U937 cells fused to a reporter gene
encoding firefly luciferase. No significant differences in luciferase activity were detected, suggesting that the translational
regulation and protein stability of FPR1 are modulated by factors other than the SNP codon bias and the variant amino acid
properties. Deletion and mutagenesis analysis of the FPR1 promoter showed that a CCAAT box is not required for gene
transcription. A 288/41 promoter construct resulted in the strongest transcriptional activity, whereas a 272/41 construct
showed large reduction in activity. The region between 288 and 272 contains a consensus binding site for the
transcription factor PU.1. Mutagenesis of this site caused significant reduction in reporter gene expression. The PU.1 binding
was confirmed in vivo by chromatin immunoprecipitation, and the binding to nucleotides 284 to 276 (TTCCTATTT) was
confirmed in vitro by an electrophoretic mobility shift assay. Thus, similar to many other myeloid genes, FPR1 promoter
activity requires PU.1. Two single nucleotide polymorphisms at 256 and 254 did not significantly affect FPR1 gene
expression, despite differences in binding of transcription factor IRF1 in vitro. Inflammatory mediators such as interferon-c,
tumor necrosis factor-a, and lipopolysaccharide did not increase FPR1 promoter activity in myeloid cells, whereas
differentiation induced by DMSO and retinoic acid enhanced the activity. This implies that the expression of FPR1 in myeloid
cells is developmentally regulated, and that the differentiated cells are equipped for immediate response to microbial
infections.
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Introduction
Formyl peptide receptor 1 (FPR1) is a G protein-coupled
receptor that mediates important host defense functions such as
chemotaxis and killing of microorganisms through phagocytosis
and oxidative burst [1]. The coding sequence of FPR1 contains ten
single nucleotide polymorphisms (SNPs); six are non-synonymous,
resulting in amino acid changes, and four are synonymous [2–4].
Most of the SNPs do not exhibit strong linkage disequilibrium,
resulting in a large number of variants, with .30 sequenced
haplotypes identified in Caucasians so far [4]. GenBank reports an
additional 7 SNPs (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.
cgi?locusId=2357), but most of them have not yet been validated.
FPR1, which contains 350 amino acids, could theoretically be
encoded in .10
183 ways, with each adjacent pair of amino acids
encoded by 2–36 different pairs of synonymous codons. However,
some codons are used more or less frequently, indicating a certain
codon bias [5]. For example, in humans, GTG is used 4 times
more frequently than GTA to encode valine, and CTG is used 5.1
times more frequently than TTA to encode leucine (http://www.
kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=9606). Simi-
larly, codon pairs are used more or less frequently than expected,
but not always following the codon bias frequencies. Based on the
codon frequencies mentioned above, the amino acid pair Val-Leu
is expected to be encoded by GTG-CTG much more frequently
than GTA-TTA, but in fact this sequence is encoded somewhat
less frequently by GTG-CTG than by GTA-TTA (codon pair bias
scores of 0.144 and 0.397, respectively) (www.sciencemag.org/cgi/
content/full/320/5884/1784/DC1; [6]). A study of the poliovirus
capsid protein showed compelling evidence that codon pair usage
affects protein translation: Large DNA molecules containing over-
or underrepresented synonymous codon pairs encoding poliovirus
capsid protein were expressed in human HeLa cells and the rate of
protein translation was measured; DNA with underrepresented
codon pairs caused decreased rates of protein translation and
attenuation of poliovirus [6]. The reason for the poor translation
efficiency is thought to be certain tRNAs that interact poorly on
the ribosomal A- and P-sites of underrepresented codon pairs [7].
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28712Similarly, the poor translation efficiency in the presence of
infrequent codons is thought to be the limiting amount of tRNAs
[8]. Since we have previously observed variable expression levels
of FPR1 in neutrophils from human donors, we investigated the
possibility that certain combinations of FPR1 SNPs may affect the
quantity of translated FPR1.
In addition to translation efficiency, protein expression levels
depend on other factors such as gene transcription, mRNA
Table 1. Codon bias and codon pair bias scores for FPR1 variants calculated based on the codons for ten validated SNPs.
FPR1 haplotype Amino acid number Codon bias Codon pair bias
11 47 101 102 116 182 190 192 331 356
1A T V V F-t I-c P-c R K T-c A 189.9 20.900
1C T V V F-t I-c P-c R K T-t A 184.1 21.107
2A T V V F-t I-c P-c W N-c T-c A 178.3 21.854
3A I V V F-t I-c P-c R N-t T-c E 209.1 +0.443
3C I V V F-t I-t P-a R N-t T-c E 201.4 20.783
4A I V L F-t I-c P-c R N-t T-c A 182.0 +1.085
5A T V L F-t I-c P-c R K T-c A 195.0 +0.471
6A T V L F-t I-c P-c R N-t T-c A 180.1 +0.932
8A I V V F-t I-c P-c R N-t T-c A 174.0 21.765
9A I V V F-t I-c P-c R K T-c A 191.8 20.747
10A I V L F-t I-c P-c R K T-c A 196.5 +0.625
11A T V V F-t I-c P-a R N-t T-c A 172.1 21.918
12B T V V F-t I-c P-c R N-t T-c E 207.2 +0.380
12C T V V F-t I-c P-a R N-t T-c E 204.3 21.098
12D T V V F-c I-c P-c R N-t T-c E 209.9 +2.346
16A T V V F-c I-c P-c R K T-c E 224.8 +1.796
25A T A L F-t I-c P-c R K T-c E 227.2 +1.202
Haplotype designations 1A-16A are by Sahagun-Ruiz et al. [2]. B, C and D show haplotypes in which the SNP does not change the amino acid compared to A [4]. The
table includes the FPR1 SNPs in the following order: c.32C.T/p.T11I, c.140T.C/p.V47A, c.301G.C/p.V101L, c.306T.C/p.F102F, c.348C.T/p.I116I, c.546C.A/p.P182P,
c.568A.T/p.R190W, c.576T.G.C/p.N192K, c.993C.T/p.T331T, c.1037C.A/p.A356E. The codon bias results show the differences between the various haplotypes based
on the total of each SNP codon usage score, as obtained from the GenBank Homo sapiens Codon Usage Database (http://www.kazusa.or.jp/codon/cgi-bin/showcodon.
cgi?species=9606). The codon pair bias results show the differences between the various haplotypes based on the total of each SNP codon pair score, as calculated
from the Supplemental Material by Coleman et al. www.sciencemag.org/cgi/content/full/320/5884/1784/DC1 [6]. Amino acids are shown in single letter code. The
nucleotide in the 3
rd position of the synonymous codons is as shown.
doi:10.1371/journal.pone.0028712.t001
Figure 1. Four FPR1 variants show similar expression levels. FPR1 haplotypes 8A, 11A, 12D and 16A were expressed as fusion proteins with
firefly luciferase in U937 cells. Cells were electroporated with various amounts of the firefly luciferase reporter plasmid (as shown) and 300 ng pRL-TK
Renilla luciferase control reporter plasmid. 24 h post-transfection cell extracts were analyzed using the Promega dual luciferase assay kit. The graphs
show the mean ratios of firefly and Renilla luciferase from five separate experiments 6 S.E.M. One-way analysis of variance showed no statistical
differences between the haplotypes.
doi:10.1371/journal.pone.0028712.g001
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about the role of these factors on the regulation of FPR1. A study
using thioglycolate-elicited mouse peritoneal macrophages and
neutrophils showed increased FPR1 mRNA stability upon
exposure to lipopolysaccharide (LPS) and a barely detectable
increase in FPR1 gene transcription [9]. To further explore the
control of FPR1 expression at the level of gene transcription, we
determined the minimal functional FPR1 promoter, studied the
role of two SNPs on transcriptional regulation, and examined the
binding of putative transcription factors to the core promoter. We
also confirmed that differentiation of human myeloid U937 cells
with DMSO and retinoic acid increases FPR1 expression [10,11].
However, unlike many cell surface proteins involved in innate
immune defense, FPR1 expression does not appear to be
transcriptionally induced in response to activators such as tumor
necrosis factor-a (TNFa), lipopolysaccharide (LPS) and interferon-
c (IFNc), suggesting that FPR1 transcription is controlled by cell
differentiation rather than inflammatory activators. This concurs
with the observed distribution of FPR1 in band cells, segmented
cells and polymorphonuclear neutrophils (PMNs) [12].
Materials and Methods
Human subjects
A total of 69 Caucasians from the Montana State University
Blood Donor Program participated in the study. The study was
approved by the Institutional Review Board of Montana State
University and the blood donors gave their informed written
consent to the study.
Construction of pGL4.10[luc2] reporter plasmids
Genomic DNA was isolated from healthy donors from 250 ml
whole blood using E.Z.N.A. Blood DNA Kit II according to the
manufacturer’s instructions (Omega Biotek). FPR1 haplotypes 8A,
11A, 12D and 16A were amplified by PCR, cloned into pGEMH-
T Easy vector (Promega) and sequenced [4]. The FPR1 inserts
were excised with Eco RI, subcloned into pBGSA vector, and the
correct orientations of the inserts were verified by restriction
mapping. The pBGSA mammalian expression vector (GenBank
Accession #AY6607190) contains a hybrid SRa promoter
composed of the simian virus 40 early promoter and the R-U5
segment of human T-cell leukemia virus type 1 long terminal
repeat [13]. The SRa promoter was used to drive expression of the
FPR1-firefly luciferase fusion protein. The promoter and the full-
length FPR1 cDNA were amplified by PCR using primers
containing restriction sites Kpn I and Bgl II to allow subcloning
in frame with the luc2 gene in the pGL4.10[luc2] vector (Promega;
GenBank Accession #AY738222).
Human FPR1 promoter amplification and sequencing
The promoter sequence of FPR1 was amplified from 100 ng
genomic DNA by PCR. Amplification utilized the following
Table 2. SNP genotyping of the FPR1 promoter in Caucasians.
256 position 254 position Number of cases n=69 Frequency
C/C G/G 31 0.449
C/T G/G 21 0.304
T/T G/G 13 0.188
C/C G/C 3 0.043
C/T G/C 1 0.011
T/T G/C 0 0.000
C/T C/C 0 0.000
T/T C/C 0 0.000
The SNP nucleotide positions are numbered based on the 59-most transcription
start site, as described by Murphy et al. [14].
doi:10.1371/journal.pone.0028712.t002
Figure 2. Identification of the minimal promoter region of FPR1. Serial deletion fragments of the FPR1 promoter were generated by PCR and
cloned upstream from the luciferase reporter gene in the pGL3 Basic vector. 10 mg of pGL3-Control vector containing the SV40 promoter was used as
positive control and 30 mg of pGL3-Basic lacking a promoter was used to measure background luminescence. The amount of pGL3-Basic-FPR1
promoter plasmids in all experiments was 30 mg. U937 cells were co-electroporated with the firefly luciferase plasmids and 300 ng of pRL-TK as a
transfection standard. Results show the mean ratios of firefly to Renilla luciferase 24 hours post-transfection from 6–19 separate experiments 6 S.E.M.
Unpaired t test demonstrated that the luciferase activity of the 272/41 construct was significantly lower than the activity of the 288/41 construct,
**p-value,0.01. Abbreviation: TSS, transcriptional start site.
doi:10.1371/journal.pone.0028712.g002
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where the first nucleotide of the primer is indicated by its position
relative to the guanidine (+1) in the transcriptional start site [14],
followed by F or R for forward or reverse and the number of
nucleotides in the primer. SNP genotypes were identified by direct
sequencing of the PCR product; haplotypes were verified after
ligation of the PCR amplicons into pGEMH-T Easy.
Luciferase vector construction
Reporter vectors were constructed in the pGL3 Basic luciferase
vector (Promega; GenBank Accession # U47295). The desired
promoter regions (2395/41, 2274/41, 2149/41, 2140/41,
2122/41, 2105/41, 288/41, 272/41 and 250/41) were
amplified by PCR using the 256C/254G haplotype as template.
The forward primers included an Xho I-site and the reverse primer
included a Hind III-site for subcloning into pGL3 Basic. The FPR1
promoter 288/41 256T/254C was constructed as above using a
256T/254C variant as template. FPR1 promoter constructs 288/
41 256C/254C and 288/41 256T/254C were created by
QuickChange
TM site-directed mutagenesis using pGL3 Basic-FPR1
promoter 288/41 256C/254G as template (Stratagene). To
remove putative transcription factor binding sites, mutations in
pGL3 Basic-FPR1 2149/41 (256C/254G) were created using
mutagenic primers as follows: NF-Y, 59(-140) -GCAGACAGTA-
TATTAATGTATTCTTGGGG-39; PU.1, 59(-95) -GAAGCTCA-
GACTTAATATTTCCTGCTACC-39; STAT-4, 59(-91) -CTCA-
GACTTCCTATGGCCTGCTACCCAG-39. Mutated sequences
are underlined. All constructs were confirmed by sequencing.
Transient transfection and dual luciferase assay of U937
cells
U937 cells (ATCCH Number: CRL-1593.2
TM) were resus-
pended at a density of 1.5610
6 cells/ml in RPMI-1640
supplemented with 10% FBS, 50 U/ml penicillin and 50 mg/ml
streptomycin. 400 ml cell suspension was added to electroporation
cuvettes (0.4 cm gap), followed by 20 mg luciferase reporter
plasmids (or as indicated in the figure legends) and 300 ng pRL-
TK vector (to normalize transfection efficiency) (Promega;
Accession # AF025848). Cells were electroporated using a BTX
ECMH399 pulse Generator with Personal Electroporation Pak 1 at
200 V, 1050 mF, and moved to wells in a 24 well plate containing
400 ml RPMI-1640 supplemented with 10% FBS, 50 U/ml
penicillin, and 50 mg/ml streptomycin. Cells were grown as
indicated in the figure legends with or without DMSO and
activating factors. Transfected cells were assayed after 24–48 h (as
indicated in figure legends) for firefly and Renilla luciferase activity
using the Dual-Luciferase Reporter Assay System (Promega) in a
Berthold EG&G Lumat Luminometer LB 96V [15].
Figure 3. Location of putative transcription factor binding sites on FPR1 promoter. A. Sequence analysis using PROMO3 software
identified certain transcription factors commonly expressed in myeloid cells as putative regulators of FPR1 transcription. The numbers indicate the
first nucleotide of the various promoter constructs in relation to the transcriptional start site (TSS). The 256 and 254 SNPs are underlined and the
various mutations of putative transcription factor binding sites are in bold. B. Site-directed mutagenesis of the putative PU.1 and STAT4 binding sites
resulted in a significant decrease in firefly luciferase activity. U937 cells were co-transfected with the indicated wild-type and promoter mutant
constructs and pRL-TK to normalize for transfection efficiency. Data show the mean ratios from three experiments 6 S.E.M. One-way analysis of
variance showed that differences in luciferase activity among the constructs were significant (p value,0.0001), and unpaired t test showed that the
luciferase activities of each of the PU.1 and STAT4 mutant constructs were significantly lower than that of the wild-type construct, p value#0.0005.
doi:10.1371/journal.pone.0028712.g003
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real-time PCR (q-PCR)
2.5610
7 U937 cells were plated at a density of 1.2610
6 cells/ml
and grown for 24 h before each experiment. Cells were incubated
for 10 min at room temperature with 0.1 volume of cross-linking
mix (11% formaldehyde, 100 mM NaCl, 0.5 mM Na-EGTA and
50 mM Na-HEPES, pH 8.0), and the reaction was quenched by
the addition of 0.125 M glycine (final concentration). Cells were
washed with Dulbecco’s PBS containing 450 mM CaCl2, 245 mM
MgCl2, 0.1% dextrose and 0.1% BSA. To prevent proteolysis,
cells were incubated for 15 min on ice with diisopropyl
fluorophosphate (DFP), washed as above and lysed in 1% SDS,
10 mM Na-EDTA (pH 8.0), 50 mM Tris-HCl (pH 8.0), 1 mM
PMSF, and a mammalian protease inhibitor cocktail (Sigma).
After 5 min incubation on ice, samples were sonicated 14610 sec
on setting 5 with a 50 Sonic Dismembrator (Fisher Scientific) to
obtain chromatin with an average size of about 600–800 bp (as
judged by gel electrophoresis). The sample was centrifuged 15 min
at 20,8006ga t4 uC to remove cell debris, and an aliquot of the
supernatant was reserved for input in PCR analysis. The rest of the
supernatant was diluted with a buffer containing 1% Triton X-
100, 150 mM NaCl, 2 mM Na-EDTA (pH 8.0), 20 mM Tris-HCl
(pH 8.0), 1 mM PMSF and protease inhibitor cocktail. Samples
were incubated on a rotator overnight at 4uC with antibody
against PU.1 (sc22805X; Santa Cruz Biotechnology) or with an
irrelevant antibody as a negative control. Antibody-DNA
complexes were precipitated with Protein A-agarose beads (Sigma)
previously blocked with BSA and salmon sperm DNA (to reduce
background binding). The beads were washed three times with
wash buffer #1 (1% Triton X-100, 0.1% SDS, 150 mM NaCl,
2 mM EDTA, 20 mM Tris-HCl, pH 8.0+protease inhibitors),
once with wash buffer #2 (same as #1 with NaCl increased to
500 mM), and finally with wash buffer #3 (20 mM Tris-HCl,
pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% Na-
deoxycholate, + protease inhibitors). The immune complexes were
eluted from the beads by 30 min incubation at 37uC with 100 mM
NaHCO3, 1% SDS, and the supernatants were treated for 30 min
with 500 mg/ml RNase A and 500 mg/ml Proteinase K at 37uC.
The cross-links were reversed after addition of 200 mM NaCl at
65uC overnight. DNA was purified by phenol-chloroform-
isoamylalcohol (25:24:1) extraction and precipitated by ethanol
in the presence of linear polyacrylamide carrier. The sonicated
input DNA was treated as above, starting with the RNaseA and
Proteinase K incubation. Precipitated DNA was resuspended in
sterile water. qPCR was carried out from the affinity-precipitated
chromatin using Quantace 26Sensimix and primers correspond-
ing to the promoter region of FPR1 (nucleotides 287 to 237). The
PCR product of 324 bp was quantified using Rotor-Gene software
and visualized by 1.5% agarose gel electrophoresis.
In vitro translation of human PU.1 and IRF1 and
electrophoretic mobility shift assay (EMSA)
The human PU.1 and IRF1 cDNAs were amplified by reverse
transcriptase PCR from human neutrophil total RNA using
forward primers spanning the start sites and including a Sal I
restriction site, and reverse primers spanning the stop site and
including a Bam HI restriction site. The amplified PCR products
were cloned into pGEMH T Easy and the sequences were
confirmed. The cDNAs were subcloned into Sal I/Bam HI site in
pSP64 poly(A) (Promega) and in vitro transcribed and translated
using the TNTH SP6 high-yield wheat germ protein expression
Figure 4. Confirmation of PU.1 binding to FPR1 promoter by
ChIP-qPCR. A. Cross-linked chromatin from U937 cells was sonicated
to obtain an average DNA length of 600–800 bp. Immunoprecipitation
was carried out using irrelevant control IgG or IgG against PU.1. The
bands correspond to PCR products obtained amplifying a 324 bp
fragment containing the putative PU.1 site (287 to 237). The input DNA
was obtained prior to the immunoprecipitation and represents ,4% of
the chromatin used in the immunoprecipitation. B. Cross-linked
immunoprecipitated chromatin from U937 cells and human neutrophils
was quantified by real-time qPCR and the amount of product was
determined relative to the input chromatin. Each bar represents the
mean ratio from three experiments 6 S.E.M.
doi:10.1371/journal.pone.0028712.g004
Table 3. PU.1 recognition in human neutrophil genes.
Gene Sequence Reference
MHC Class II TTCCTCTTT [22]
CD11b TTCCTCTTT [23]
gp40
phox TTCCTCTTA [24]
gp47
phox TTCCTCTTT [25]
gp67
phox TTCCTCTCT [26]
gp91
phox TTCCTCATT [16]
FPR1 TTCCTATTT This study
The consensus sequence for PU.1 binding is shown in bold.
doi:10.1371/journal.pone.0028712.t003
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35S]methionine according to manufac-
turer’s protocol (Promega). A negative control reaction was carried
out using the pSP64 poly(A) plasmid in the absence of a cDNA
insert (
35S-control). The
35S-PU.1 and
35S-IRF1 products were
electrophoresed on a SDS-polyacrylamide gel, and the gel was
subjected to autoradiography to confirm the correct molecular
masses of the proteins. Double-stranded oligonucleotide probes
spanning FPR1 promoter region 2101 to 263 (containing a
putative PU.1 binding site) and 273 to 244 (containing a putative
IRF1 binding site) were incubated for 20 min at room temperature
in the absence or presence of
35S-PU.1,
35S-IRF1, or
35S-control
reaction in a buffer containing 10 mM Tris-HCl, pH 7.6, 50 mM
KCl, 1 mM MgCl2, 5% glycerol, 0.5 mM EDTA, 1 mM DTT
and 100 ng/ml sonicated salmon sperm DNA. Samples were run
using the Mini-PROTEANH 3 cell (Bio-Rad) on 6% non-
denaturing polyacrylamide gels (19:1) in 0.56TBE at 100 V for
90 min. Gels were fixed and subjected to autoradiography.
Control double-stranded oligonucleotide for PU.1 was derived
from the promoter region of gp91
phox [16], and control IRF1
double-stranded oligonucleotide was designed based on the
published IRF1 binding consensus sequence, flanked by FPR1
promoter sequence [17].
Flow cytometry
U937 cells at a concentration of 2.5610
5 cells/ml were
incubated for 0–5 days in the presence of 1% DMSO. Cells were
Figure 5. Confirmation of PU.1 binding to FPR1 promoter by EMSA. A. The following oligonucleotide dimers were used in the binding
assays: gp91
phox with a known PU.1 binding site (positive control); FPR1 with a putative PU.1 binding site; two FPR1 oligodimers with nucleotide
substitutions (underlined) in the putative binding site. B. In vitro synthesized
35S-PU.1 was incubated with or without gp91
phox and FPR1 wild-type
and mutant oligonucleotide dimers, as shown. C. Dose-dependence of
35S-PU.1binding was shown using 10–200 ng of gp91
phox and FPR1
oligodimers.
doi:10.1371/journal.pone.0028712.g005
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5% FBS, 20 nM N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys-fluorescein
(a ligand that binds FPR1), and 1 mg/ml propidium iodide (a
fluorescent dye used to measure cell viability). Cells were
incubated for 1 h on ice, followed by analysis of 10,000 cells
using a BD Biosciences FACSCalibur flow cytometer. The scatter
plots were gated to show the percentage of cells that did not bind
ligand (FPR1 negative cells), cells that bound ligand (FPR1 positive
cells) and non-viable cells (propidium iodide positive cells).
Results
SNP codon bias and codon pair bias do not affect the
expression levels of FPR1
As mentioned in the Introduction, codon bias and codon pair
bias affect the transcription and translation of both prokaryotic
and eukaryotic proteins. To examine whether FPR1 haplotypes
previously amplified and sequenced by us have variable protein
expression, the scores for the various SNP combinations were
calculated [4]. As shown in Table 1, which contains a partial list
of the 31 haplotypes, the differences based on codon bias were
relatively small, whereas the codon pair bias scores showed larger
variation. Based on the results, we selected two haplotypes from
opposite ends of the scores; haplotypes 8A and 11A as FPR1
variants predicted to have low expression levels, and 12D and
16A as FPR1 variants predicted to have high expression levels on
the basis of codon pair bias scores. The coding sequences linked
to a strong promoter were inserted into the pGL4.10 [luc2] vector
to create FPR1-luciferase fusions. Human myeloid U937 cells were
co-transfected with various amounts of these plasmids and a
constant amount of the pRL-TK vector which drives the
expression of Renilla luciferase under the TK promoter (as an
internal standard for transfection normalization). As shown in
Figure 1, the relative amounts of FPR1-luciferase fusion proteins
were very similar, with no statistical differences between the
various haplotypes. Thus, the codon bias and codon pair bias
differences based on the SNPs in the coding region of FPR1 do
not appear to affect the expression levels of the receptor in
transfected U937 cells.
Genotyping of FPR1 promoter
The FPR1 gene contains a single promoter region previously
described by several groups [14,18,19]. The Human Genome
Sequencing Project identified a single SNP in the FPR1 promoter
region, 256C.T (rs4802859), relative to the transcription start site
(GenBank accession number NT_011109.16). To determine the
relative frequency of this SNP, we carried out PCR amplification
and sequencing of the promoter from 69 American Caucasians. We
found that 18.8% of the individualswerehomozygous forthe 256T
allele, similar to 15.9% in the European population reported by the
HapMap project (http://www.ncbi.nlm.nih.gov/projects/SNP/
snp_ref.cgi?rs=4802859). Our studies also revealed a second SNP
in this region, 254G.C (rs62108945), with an occurrence of 5.8%
heterozygousindividuals and 0%homozygous individuals (Table 2).
No genotyping data are available at this time in the GenBank for
this SNP (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.
cgi?rs=62108945). The most common genotype among Cauca-
sianswas256C/C,254G/G,withanoccurrenceof45%(Table2).
Localization of FPR1 promoter activity
To identify the minimal promoter region for transcriptional
activity of FPR1, nine different FPR1 promoter fragments ranging
in size from 91 to 436 bp were cloned upstream of the luciferase
reporter gene in vector pGL3 Basic (Figure 2). The nucleotide
sequence was enumerated relative to the 59-most transcriptional
start site (TSS), designated nucleotide +1 [14]. The promoter
constructs were co-transfected into U937 cells with the
quantitative control vector, pRL-TK. Similar expression levels
of firefly luciferase were observed with the five largest promoter
fragments (2395/41, 2274/41, 2149/41, 2140/41, and
2122/41), whereas two smaller promoter fragments (2105/41
and 288/41) appeared to result in somewhat higher expression,
although the differences were not statistically significant
(Figure 2). Additional deletion of 16 nucleotides (272/41),
resulted in a significant drop in expression levels (Figure 2).
Based on these results, the most important region for
transcriptional activation of the FPR1 gene appears to be
between nucleotides 288 and 272.
Mutagenesis studies of the FPR1 promoter
The FPR1 promoter sequence between 2149 and +1 was
analyzed using the Promo3 software (http://alggen.lsi.upc.es/cgi-
bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) to identify
possible binding sites for transcription factors [20,21]. We
identified a putative NF-Y binding site at 2129 to 2123, a
putative PU.1 binding site at 284 to 279, a putative STAT4
binding site at 279 to 273, a putative IRF1 binding site at 261 to
252 in the 256C/254C promoter, and a putative PU.1 site at
259 to 253 in the 256C/254C promoter (Figure 3). To examine
whether the NF-Y, PU.1 and STAT4 sites are important for FPR1
expression, mutations in these sites were generated using the
Figure 6. PU.1 does not bind the putative binding site in the
256/254 SNP region of the promoter. A. Oligonucleotide dimers
of gp91
phox with a known PU.1 binding site and FPR1 with the four
possible 256/254 SNP combinations were used in EMSA. B. In vitro
synthesized
35S-PU.1 was incubated with gp91
phox and the various FPR1
oligonucleotide dimers. Where indicated, the incubation was carried
out with a negative control (in vitro transcription/translation product
using vector alone) or in the absence of oligodimer.
doi:10.1371/journal.pone.0028712.g006
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elimination of the putative NF-Y binding site (and CCAAT box)
did not decrease the amount of firefly luciferase, but mutagenesis
of the putative PU.1 and STAT4 binding sites, either individually
or together, caused a significant decrease in transcriptional
activity.
Figure 7. IRF1 binds the putative binding site in the 256/254 SNP region of the promoter. A. Oligonucleotide dimers of IRF1 consensus
binding sequence and FPR1 with the four possible 256/254 SNP combinations were used in EMSA. B. In vitro synthesized
35S-IRF1 was incubated
with IRF1 consensus dimer and the various FPR1 oligonucleotide dimers. Where indicated, the incubation was carried out with a negative control (in
vitro transcription/translation product using vector alone) or in the absence of oligodimer. C. The binding of
35S-IRF1 to the various oligodimers was
quantified by densitometry of the autoradiographic films. The results show the means 6 S.E.M. from three experiments. One-way analysis of variance
showed that the differences in luciferase activity among the FPR1 constructs were significant (P,0.0001), and unpaired t test showed a significant
difference between C/G and each of the other FPR1 SNP constructs. **p-value,0.05, ***p-value,0.001.
doi:10.1371/journal.pone.0028712.g007
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Chromatin immunoprecipitation (ChIP) and quantitative real-
time PCR (qPCR) were carried out to interrogate binding of
PU.1 to the FPR1 promoter. Chromatin fragments that bound to
anti-PU.1 were PCR amplified with primers encompassing the 287
to +237 region of the promoter. As shown in Figure 4, U937 cells
and human neutrophils showed a significant enrichment of the
amplified FPR1 promoter immunoprecipitated with the anti-PU.1
antibody compared to mock immunoprecipitation (Control IgG).
Since our reporter assays suggested that the dual PU.1/STAT4
mutant did not result in further reduction in FPR1 promoter activity
comparedtoPU.1orSTAT4alone,weexaminedthepossibilitythat
the second mutation in the putative STAT4 binding site may in fact
inhibit the binding of PU.1. Our hypothesis gained further support
upon examination of the nucleotide sequences immediately
downstream of the known PU.1 binding sites of a number of
promoters. As shown in Table 3, thymine is relatively conserved in
positions 1, 2 and 3 immediately after the established PU.1 binding
sequence,TTCCTC[16,22–26].Tostudytheroleofthesethymines
in the binding of PU.1 to the FPR1 promoter, and to confirm the
binding to the 284 to 276 site, we carried out electrophoretic
mobility shift assays (EMSA) using wild-type and mutant promoter
sequences, as shown in Figure 5A. Figure 5B shows
35S-PU.1
binding to an oligodimer containing the known gp91
phox binding site
(used as a positive control) [16] and to the FPR1 wild-type
oligodimer, but not to the mutant FPR1 oligodimer containing two
substitutions in the putative TTCCT PU.1 binding site (mutant #1).
Inaddition,substitutionsof two thymineswith guaninesdownstream
of the TTCCT site also prevented the binding of PU.1 (mutant #2).
These results confirm the PU.1 binding in the FPR1 promoter and
suggest that the binding region may include up to 9 nucleotides
(TTCCTATTT). To compare the binding affinity of PU.1 to the
gp91
phox and the FPR1 oligodimers, we carried out EMSA using
various quantities of each oligodimer. As shown in Figure 5C,
35S-
PU.1 appeared to bind to the gp91
phox oligodimer with somewhat
higher affinity than to the FPR1 oligodimer. The minor difference in
binding affinity may in part be because position 6 of the FPR1
binding site is adenine rather than cytosine, the more commonly
observed nucleotide in this position (Table 3).
Effect of 256/254 SNPs on transcription factor binding
As mentioned above, the PROMO3 analysis identified the
256/254 SNP region of the FPR1 promoter as another potential
binding site for transcription factors. In particular, the 256C/
254C variant showed some homology with the consensus
sequences for PU.1 and IRF1 binding (Figures 6A and 7A).
Incubation with
35S-PU.1, however, did not result in binding to
any of the FPR1 256/254 variant oligodimers (Figure 6B). Thus,
the FPR1 minimal promoter region appears to contain only one
PU.1 binding site located at nucleotides 284 to 276. EMSA
using in vitro translated
35S-IRF1 resulted in good binding to the
256C/254C oligodimer, slightly lower binding to the 256C/
254G oligodimer, and strongly reduced binding to 256T/254G
and 256T/254C oligodimers (Figure 7B and 7C). To examine
whether this difference in IRF1 binding to the FPR1 promoter
variants affects transcriptional regulation, we measured the
promoter activity using the 288/41 FPR1 minimal promoter
construct with the various SNP combinations. The differences
between the promoter variants were not statistically significant,
suggesting that IRF1 does not play a major role in the
transcriptional regulation of FPR1 in U937 cells (Figure 8). This
conclusion is also supported by the results with the 272/41
promoter showing significantly reduced reporter gene activity
compared to the 288/41 promoter (Figure 2). The results were
similar in the presence of interferon-c, a inflammatory activator
known to rapidly induce IRF1 expression in U937 cells [27],
suggesting that the results shown in Figure 8 were not simply due
to low levels of IRF1 in the cells (data not shown).
Cell differentiation of U937 cells with DMSO and retinoic
acid increase the promoter activity of FPR1
It has been previously established that U937 cells and HL-60 cells
become differentiated in the presence of DMSO, resulting in
expression of many immune receptors, including FPR1 [10,11]. We
confirmed the DMSO effect on FPR1 synthesis using our FPR1
promoter 2149/41 C/G-luciferase reporter construct (Figure 9A
and 9B). A significant increase in activity could be detected 48 h
after transfection in the presence of 1% DMSO compared to no
DMSO (Figure 9A). The highest ratios were observed when cells
were incubated in the presence of DMSO for 2–4 days prior to
transfection (Figure 9B). The Renilla luciferase activity decreased
with the longer incubation times in DMSO, however, with activity
barely above background after 4 days in DMSO (Figure 9B),
presumably because of a combination of increased cell death and
lower electroporation efficiency [28]. Comparable results were
obtained when the time-dependent effect of DMSO on endogenous
FPR1 expression was examined in U937 cells by flow cytometry
(Figure 9C and S1). We then examined the effect of various
activating and priming agents on the transcriptional regulation of
FPR1 and found a statistically significant increase in the presence of
all-trans-retinoic acid (RA), but not in the presence of tumor necrosis
factor-a (TNFa), 1,25 (OH)2-vitamin D3 (D3), lipopolysaccharide
(LPS), or interferon-c (IFNc) (Figure 10A). The effect of retinoic
acid was concentration dependent, with a significant increase in
reporter activity at 1 mM (Figure 10B).
Discussion
Translation of eukaryotic proteins is regulated on multiple levels
during initiation, elongation and termination. It is believed that
the efficiency of translation elongation is in part determined by
Figure 8. No significant differences in transcriptional activity
between the four promoter variants were detected. FPR1
minimal promoters 288/41 256C/254G, 256T/254G, 256C/254C
and 256T/254C were cloned upstream from the luciferase reporter
gene, electroporated into U937 cells and expression was analyzed in a
dual luciferase assay, as previously described. The graphs show the
mean ratios from seven experiments 6 S.E.M. The differences are
statistically not significant in one-way analysis of variance, p
value=0.391.
doi:10.1371/journal.pone.0028712.g008
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However, recent actively debated work in prokaryotes has shown
that mRNA folding may play a predominant role in translation
efficiency [29–31]. Similar studies in eukaryotes are few and
controversial, but recent studies suggest that although codon bias
plays an important role in translation efficiency [32], two-thirds of
the variation in protein abundance can be attributed to mRNA
abundance and sequence features related to translation and protein
degradation [33]. The strongest individual correlates of protein
expression were the length of the mRNA sequence, amino acid
properties, upstream open reading frames and secondary structures
in the 59 untranslated region [33]. Studies of the cytoskeletal protein
actin provided strong evidence for the importance of nucleotide
content. The two isoforms of actin, b and c, have almost
indistinguishable amino acid sequences, but use alternate codons.
c-actin is translated more slowly than b-actin, exposing a lysine
residue for ubiquitination, resulting in more rapid degradation of
the protein [34]. Our studies focused on the hypothesis that codon
bias and codon pair bias in FPR1 gene variants may affect protein
synthesis and/or stability. Our current results indicate that the
codon differences and the variations in the amino acid properties of
the different FPR1 haplotypes do not affect the abundance of FPRs.
This confirms that translational regulation and protein stability are
modulated by multiple factors and can be quite variable from one
type of protein to another.
Figure 10. Retinoic acid in the presence of DMSO further
increases FPR1 promoter-mediated transcription. A. Cells were
co-transfected with pGL3 Basic-FPR1 2149/41 and pRL-TK and
incubated for 48 h in the presence of 1% DMSO 6 100 U/ml tumor
necrosis factor a (TNFa), 1 mM all-trans retinoic acid (RA), 10 nM 1,25
(OH)2-vitamin D3 (D3), 100 ng/ml lipopolysaccharide (LPS) and 500 U/
ml interferon c (IFNc). The results are from three experiments 6 S.E.M.
Unpaired t test, * p-value,0.05. B. Cells were co-transfected with the
pGL3 Basic-FPR1 2149/41 plasmid and pRL-TK and incubated for 48 h
in the presence of 1% DMSO 6 various concentrations of all-trans
retinoic acid (as shown). The graphs show the mean ratios from four
experiments 6 S.E.M. Unpaired t test, * p-value,0.05.
doi:10.1371/journal.pone.0028712.g010
Figure 9. DMSO increases FPR1 promoter-mediated transcrip-
tion. A. Cells were co-transfected with pGL3 Basic-FPR1 2149/41 and
pRL-TK and incubated for 48 h in the presence or absence of DMSO
prior to dual luciferase assay. The graphs show the mean ratios from
four experiments 6 S.E.M. Unpaired t test, *** p-value,0.0001. B. Cells
were incubated for a total of 0–4 days in the presence of 1% DMSO
prior to co-transfection with pGL3 Basic-FPR1 2149/41 and pRL-TK.
Cells were then incubated for another 24 h in the presence or absence
of DMSO before dual luciferase assay. The white bars show the firefly
luciferase/Renilla luciferase ratio, and the black bars show the Renilla
luciferase activity in relative light units. The results show the mean
ratios of triplicate samples 6 S.E.M. C. U937 cells were incubated for 0–
5 days in the presence of 1% DMSO prior to analysis by flow cytometry.
Cells were incubated on ice for 1 h with 20 nM N-formyl-Nle-Leu-Phe-
Nle-Tyr-Lys-fluorescein and 1 mg/ml propidium iodide, followed by
analysis of 10,000 cells. The graph shows the percentage of cells that
bound fluorescent ligand (FPR1 positive cells) and the percentage of
dead cells (propidium iodide positive cells). The scatter plots can be
seen in Figure S1 (Supporting Information).
doi:10.1371/journal.pone.0028712.g009
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tionally active. This study examined the transcriptional regulation of
FPR1, with emphasis on characterizing the functional promoter,
putative transcription factor binding sites, and the role of two SNPs in
the promoter region. Traditionally, eukaryotic promoters contain
different combinations of TATA boxes, CCAAT boxes, GC boxes,
and other elements within 100–200 bp of the transcription initiation
site [35]. No individual element is essential for promoter function,
although one or more elements must be present for efficient initiation.
Murphy and co-workers have previously identified a non-consensus
TATA box (TATGTT), an inverted CCAAT box (ATTGG) and one
pyrimidine-rich segment (253 to 228) in this region of the FPR1
promoter [14]. Our results suggest that the inverted CCAAT box is
not utilized, since several promoter constructs lacking the site and also
an inverted CCAAT box mutant (ATTAA) resulted in normal
reporter gene activity. The strongest luciferase activity was obtained
with a 288/41 promoter construct containing putative binding sites
f o rP U . 1a n dS T A T 4( 284 to 273). A deletion of 16 additional
nucleotides (272/41) resulted in 5-fold decrease in luciferase activity.
Mutagenesis of the adjacent putative PU.1 and STAT4 binding sites
either individually or together reduced reporter gene activity about 4-
fold. ChIP-qPCR confirmed the in vivo binding of PU.1 to the FPR1
promoter, and EMSA confirmed the PU.1 binding site. In addition,
sequence comparisons with other known PU.1 binding promoter
sequences and EMSA analysis showed that the PU.1 binding site may
contain additional nucleotides, suggesting a consensus binding
sequence of TTCCTCTTT (TTCCTATTT in FPR1). PU.1 is a
member of the ets transcription factor family expressed in hemato-
poietic cells. It has been found at all stages of granulopoiesis, with the
highest levels in PMNs [36,37], and plays an important role in innate
immune functions of these cells. Perhaps the most notable example is
the multicomponent NADPH oxidase system. PU.1 has been found to
be an essential activator for the expression of several of its components,
including p47
phox,g p 9 1
phox,p 6 7
phox,a n dp 4 0
phox [24–26,38].
The discovery of two SNPs at a distance of 54 and 56 nucleotides
upstream from the transcriptional start site of FPR1 suggested that
they may be involved in transcriptional regulation of the gene.
Many promoter SNPs have indeed been shown to affect protein
expression, resulting in major health-related effects. For example,
an SNP in the matrix metalloproteinase-12 (MMP-12) promoter
influences the binding of transcription factor AP-1 and is associated
withcoronaryarterydisease [39],and a SNPinthe promoterregion
of interleukin 4 (IL4) affects the binding of transcription factor
NFAT, resulting in a 3-fold difference in IL4 expression [40]. We
therefore examined the possibility that the 256/254 SNPs affect
transcription factor binding and protein expression. To do this, we
compared the luciferase activity of the 288/41 promoter construct
containing all four possible SNP combinations. The differences
between the various constructs were not statistically significant,
suggesting that this region is not critical for transcription. This
conclusion was further supported by the finding that the 288/41
(C/G) and 272/41 (C/G) promoters showed a 5-fold difference in
luciferase activity, indicating that the major regulatory domain is
between nucleotides 288 and 272. However, we cannot
completely rule out the possibility that the SNP region may under
certain conditions contribute to the transcriptional regulation of
FPR1, since in vitro studies suggested that IRF1 transcription factor
preferentially binds the 256C/254C sequence. Several potential
IRF1 host defense target genes have been previously characterized,
including the NADPH component, gp91
phox [16,41].
Previous studies examining the transcriptional regulation of cell
surface proteins involved in the differentiation and inflammatory
response of myeloid cells, such as the various components of
NADPH oxidase, have identified a number of cytokines,
differentiation factors and bacterial components that up- or
down-regulate expression. The most commonly studied are TNFa,
retinoic acid, 1,25 (OH)2-vitamin D3, LPS and IFNc. For
example, the gene expression of the phagocyte cytosolic protein
p47
phox component of NADPH oxidase is up-regulated by TNFa,
retinoic acid, 1,25 (OH)2-vitamin D3, and LPS, but down-
regulated by IFNc [42–44]. In contrast, IFNc induces the
expression of FcR and certain chemokine receptors (CCR1,
CCR3 and CCR5) in U937 cells [45,46]. Our results confirmed
the previous results showing maturation and increased FPR1
expression in myeloid cells upon incubation with DMSO [10,11].
Incubation with inflammatory activators in the absence of DMSO
did not result in significant increases in FPR1 promoter activity,
and only retinoic acid, but not TNFa, 1,25 (OH)2-vitamin D3,
LPS or IFNc, further increased protein expression in the presence
of DMSO. Thus, unlike some of the other innate immune
receptors and molecules, the expression of FPR1 is dependent on
cell differentiation and maturation rather than an inflammatory
stimulus. Physiologically, this appears logical since FPR1 is one of
the first receptors that is alerted to the presence of microorganisms,
and directs the PMNs to the site of infection through chemotaxis.
A cell equipped to immediately respond to a bacterial threat likely
minimizes the damage by the invading microorganisms.
Supporting Information
Figure S1 Analysis of FPR1 expression in U937 cells by
flow cytometry. U937 cells were incubated 0–5 days with 1%
DMSO, as indicated in the figure. FPR1 expression was visualized
using a fluorescent high affinity binding ligand, N-formyl-Nle-Leu-
Phe-Nle-Tyr-Lys-fluorescein (FL-1). Propidium iodide was used to
visualize the non-viable cells (FL-2). The proportion of both FPR1-
positive cells and non-viable cells increased over time with
maximal FPR1 expression after 4–5 day incubation.
(EPS)
Acknowledgments
I thank Bruce Granger for helpful discussions, Al Jesaitis, director of the
Montana State University Blood Donor Program, for providing blood
samples, Robert Watkins for help with flow cytometry, and Jeannie
Gripentrog for help in the laboratory. I am also grateful to the Montana
State University Functional Genomics Core Facility for equipment use.
Finally, I would like to thank the anonymous reviewers for helpful
comments and suggestions.
Author Contributions
Conceived and designed the experiments: HMM. Performed the
experiments: HMM. Analyzed the data: HMM. Contributed reagents/
materials/analysis tools: HMM. Wrote the paper: HMM.
References
1. Ye RD, Boulay F (1997) Structure and function of leukocyte chemoattractant
receptors. Adv Phamacol 39: 221–289.
2. Sahagun-Ruiz A, Colla JS, Juhn J, Gao J-L, Murphy PM, et al. (2001)
Contrasting evolution of the human leukocyte N-formylpeptide receptor
subtypes FPR and FPRL1. Genes Immun 2: 335–342.
3. Zhang Y, Syed R, Uygar C, Pallos D, Gorry MC, et al. (2003) Evaluation of
human leukocyte N-formyl peptide receptor (FPR1) SNPs in aggressive
periodontitis patients. Genes Immun 4: 22–29.
4. Gripentrog JM, MillsJS, SaariGJ, Miettinen HM(2008)Variable responses offormyl
peptide receptor haplotypes toward bacterial peptides. Immunogenetics 60: 83–93.
Regulation of Formyl Peptide Receptor 1 Synthesis
PLoS ONE | www.plosone.org 11 December 2011 | Volume 6 | Issue 12 | e287125. Gutman GA, Hatfield GW (1989) Nonrandom utilization of codon pairs in
Escherichia coli. Proc Natl Acad Sci U S A 86: 3699–3703.
6. Coleman JR, Papamichail D, Skiena S, Futcher B, Wimmer E, et al. (2008)
Virus attenuation by genome-scale changes in codon pair bias. Science 320:
1784–1787.
7. Buchan JR, Aucott LS, Stansfield I (2006) tRNA properties help shape codon
pair preferences in open reading frames. Nucleic Acids Res 34: 1015–1027.
8. Ermolaeva MD (2001) Synonymous codon usage in bacteria. Curr Issues Mol
Biol 3: 91–97.
9. Mandal P, Novotny M, Hamilton TA (2005) Lipopolysaccharide induces formyl
peptide receptor 1 gene expression in macrophages and neutrophils via
transcriptional and posttranscriptional mechanisms. J Immunol 175: 6085–6091.
10. Sakano T, Fujie A, Hamasaki T, Harada Y, Taniguchi H, et al. (1988)
Intracellular Ca
2+ mobilization in immature and more mature U937 induced to
differentiate by dimethyl sulfoxide or phorbol myristate acetate. Cell Immunol
111: 390–397.
11. Erbeck K, Klein JB, McLeish KR (1993) Differential uncoupling of
chemoattractant receptors from G proteins in retinoic acid-differentiated HL-
60 granulocytes. J Immunol 150: 1913–1921.
12. Borregaard N, Sorensen OE, Theilgaard-Monch K (2007) Neutrophil granules:
a library of innate immunity proteins. Trends Immunol 28: 340–345.
13. Takebe Y, Seiki M, Fujisawa J-I, Hoy P, Yokota K, et al. (1988) SRa promoter:
An efficient and versatile mammalian cDNA expression system composed of the
simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia
virus type 1 long terminal repeat. Mol Cell Biol 8: 466–472.
14. Murphy PM, Tiffany HL, McDermott D, Ahuja SK (1993) Sequence and
organization of the human N-formyl peptide receptor-encoding gene. Gene 133:
285–290.
15. Sherf BA, Navarro SL, Hannah RR, Wood KV (1996) Dual-luciferase
TM
reporter assay: An advanced co-receptor technology integrating firefly and
Renilla luciferase assays. Promega Notes Magazine. pp 2–8.
16. Eklund EA, Jalava A, Kakar R (1998) PU.1, interferon regulatory factor 1, and
interferon consensus sequence-binding protein cooperate to increase gp91
phox
expression. J Biol Chem 273: 13957–13965.
17. Tanaka N, Kawakami T, Taniguchi T (1993) Recognition DNA sequences of
interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and
the interferon system. Mol Cell Biol 13: 4531–4538.
18. Perez HD, Holmes R, Kelly E, McClary J, Chou Q, et al. (1992) Cloning of the
gene coding for a human receptor for formyl peptides. Characterization of a
promoter region and evidence for polymorphic expression. Biochemistry 31:
11595–11599.
19. Haviland DL, Borel AC, Fleisher DT, Haviland JC, Wetsel RA (1993) Structure,
59-flanking sequence, and chromosome location of the human N-formyl peptide
receptor gene. A single-copy gene comprised of two exons on chromosome
19q.13.3 that yields two distinct transcripts by alternative polyadenylation.
Biochemistry 32: 4168–4174.
20. Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, et al. (2002)
PROMO: detection of known transcription regulatory elements using species-
tailored searches. Bioinformatics 18: 333–334.
21. Farre D, Roset R, Huerta M, Adsuara JE, Rosello L, et al. (2003) Identification
of patterns in biological sequences at the ALGGEN server: PROMO and
MALGEN. Nucleic Acids Res 31: 3651–3653.
22. Klemsz MJ, McKercher SR, Celada A, Van BC, Maki RA (1990) The
macrophage and B cell-specific transcription factor PU.1 is related to the ets
oncogene. Cell 61: 113–124.
23. Brugnoli F, Lambertini E, Varin-Blank N, Piva R, Marchisio M, et al. (2010)
Vav1 and PU.1 are recruited to the CD11b promoter in APL-derived
promyelocytes: role of Vav1 in modulating PU.1-containing complexes during
ATRA-induced differentiation. Exp Cell Res 316: 38–47.
24. Li SL, Valente AJ, Qiang M, Schlegel W, Gamez M, et al. (2002) Multiple PU.1
sites cooperate in the regulation of p40
phox transcription during granulocytic
differentiation of myeloid cells. Blood 99: 4578–4587.
25. Li SL, Valente AJ, Zhao SJ, Clark RA (1997) PU.1 is essential for p47
phox
promoter activity in myeloid cells. J Biol Chem 272: 17802–17809.
26. Gauss KA, Bunger PL, Quinn MT (2002) AP-1 is essential for p67
phox promoter
activity. J Leukoc Biol 71: 163–172.
27. Tamura T, Ueda S, Yoshida M, Matsuzaki M, Mohri H, et al. (1996) Interferon-
gamma induces Ice gene expression and enhances cellular susceptibility to
apoptosis in the U937 leukemia cell line. Biochem Biophys Res Commun 229:
21–26.
28. Chateau MT, Ginestier-Verne C, Chiesa J, Caravano R, Bureau JP (1996)
Dimethyl sulfoxide-induced apoptosis in human leukemic U937 cells. Anal Cell
Pathol 10: 75–84.
29. Kudla G, Murray AW, Tollervey D, Plotkin JB (2009) Coding-sequence
determinants of gene expression in Escherichia coli. Science 324: 255–258.
30. Plotkin JB, Kudla G (2011) Synonymous but not the same: the causes and
consequences of codon bias. Nat Rev Genet 12: 32–42.
31. Tuller T, Waldman YY, Kupiec M, Ruppin E (2010) Translation efficiency is
determined by both codon bias and folding energy. Proc Natl Acad Sci U S A
107: 3645–3650.
32. Waldman YY, Tuller T, Shlomi T, Sharan R, Ruppin E (2010) Translation
efficiency in humans: tissue specificity, global optimization and differences
between developmental stages. Nucleic Acids Res 38: 2964–2974.
33. Vogel C, Abreu RS, Ko D, Le SY, Shapiro BA, et al. (2010) Sequence signatures
and mRNA concentration can explain two-thirds of protein abundance variation
in a human cell line. Mol Syst Biol 6: 400.
34. Zhang F, Saha S, Shabalina SA, Kashina A (2010) Differential arginylation of
actin isoforms is regulated by coding sequence-dependent degradation. Science
329: 1534–1537.
35. Lewin B (2007) Promoters and Enhancers. In: Genes IX. Sudbury: Jones &
Bartlett Learning. pp 609–639.
36. Chen HM, Zhang P, Voso MT, Hohaus S, Gonzalez DA, et al. (1995)
Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B.
Blood 85: 2918–2928.
37. Bjerregaard MD, Jurlander J, Klausen P, Borregaard N, Cowland JB (2003) The
in vivo profile of transcription factors during neutrophil differentiation in human
bone marrow. Blood 101: 4322–4332.
38. Suzuki S, Kumatori A, Haagen IA, Fujii Y, Sadat MA, et al. (1998) PU.1 as an
essential activator for the expression of gp91
phox gene in human peripheral
neutrophils, monocytes, and B lymphocytes. Proc Natl Acad Sci U S A 95:
6085–6090.
39. Jormsjo S, Ye S, Moritz J, Walter DH, Dimmeler S, et al. (2000) Allele-specific
regulation of matrix metalloproteinase-12 gene activity is associated with
coronary artery luminal dimensions in diabetic patients with manifest coronary
artery disease. Circ Res 86: 998–1003.
40. Rockman MV, Hahn MW, Soranzo N, Goldstein DB, Wray GA (2003) Positive
selection on a human-specific transcription factor binding site regulating IL4
expression. Curr Biol 13: 2118–2123.
41. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N (2001) IRF family of
transcription factors as regulators of host defense. Annu Rev Immunol 19:
623–655.
42. Green SP, Hamilton JA, Uhlinger DJ, Phillips WA (1994) Expression of p47-
phox and p67-phox proteins in murine bone marrow-derived macrophages:
enhancement by lipopolysaccharide and tumor necrosis factor alpha but not
colony stimulating factor 1. J Leukoc Biol 55: 530–535.
43. Levy R, Malech HL (1991) Effect of 1,25-dihydroxyvitamin D3, lipopolysac-
charide, or lipoteichoic acid on the expression of NADPH oxidase components
in cultured human monocytes. J Immunol 147: 3066–3071.
44. Cassatella MA, Bazzoni F, Flynn RM, Dusi S, Trinchieri G, et al. (1990)
Molecular basis of interferon-gamma and lipopolysaccharide enhancement of
phagocyte respiratory burst capability. Studies on the gene expression of several
NADPH oxidase components. J Biol Chem 265: 20241–20246.
45. Harris PE, Ralph P, Litcofsky P, Moore MA (1985) Distinct activities of
interferon-gamma, lymphokine and cytokine differentiation-inducing factors
acting on the human monoblastic leukemia cell line U937. Cancer Res 45: 9–13.
46. Zella D, Barabitskaja O, Burns JM, Romerio F, Dunn DE, et al. (1998)
Interferon-gamma increases expression of chemokine receptors CCR1, CCR3,
and CCR5, but not CXCR4 in monocytoid U937 cells. Blood 91: 4444–4450.
Regulation of Formyl Peptide Receptor 1 Synthesis
PLoS ONE | www.plosone.org 12 December 2011 | Volume 6 | Issue 12 | e28712